Tenaya Therapeutics awarded CEO Ali Faraz 122,000 shares at $0 per share and 732,500 derivative securities on September 10. The share award represented 22.6% of his resulting share holding, while the derivative award represented 100.0% of his resulting derivative securities holding, giving investors separate disclosed ownership measures.
Key Highlights
- The transaction used code A, classifying both awards as grants.
- The 122,000-share award represented about 22.6% of Ali Faraz’s resulting share holding.
- The derivative-securities award represented about 100.0% of his resulting derivative securities holding.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) awarded Chief Executive Officer Ali Faraz 122,000 shares at $0 per share on September 10, bringing his resulting share holding to 539,782. The same transaction date also covered 732,500 derivative securities, with Faraz’s resulting holding listed at 732,500.
Shares and Derivative Securities Awarded
The award price was $0 per share. Tenaya Therapeutics also recorded an award of 732,500 derivative securities on September 10. Ali Faraz was the named recipient for both awards, and the transaction details separately state the resulting holdings for shares and derivative securities.
Resulting Ownership Percentages
The 122,000-share award represented about 22.6% of Faraz’s resulting share holding. The derivative-securities award represented about 100.0% of his resulting derivative-securities holding. Both percentages relate to the September 10 awards and use the holdings reported afterward.
FAQs
Q: What shares did Tenaya Therapeutics CEO Ali Faraz receive?
A: Tenaya Therapeutics awarded Ali Faraz 122,000 shares at $0 per share on September 10. The transaction used code A, meaning an award or grant.
Q: How did the Tenaya Therapeutics award affect Ali Faraz’s holdings?
A: The award brought Ali Faraz’s resulting Tenaya Therapeutics share holding to 539,782. The transaction represented about 22.6% of that resulting holding.
Q: What derivative securities did Ali Faraz receive from Tenaya Therapeutics?
A: Ali Faraz received 732,500 derivative securities on September 10. That award represented about 100.0% of his resulting derivative securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.